Deuterated (“heavy”) water labeling in CLL patients demonstrates that IGHV unmutated and ZAP-70-positive patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease (MRD) levels with long-term ibrutinib treatment. …